Anastrozole (Arimidex™) in clinical practice versus the old ‘gold standard’, tamoxifen

References

• American Cancer Society Cancer Facts and Figures (2002).
   Google Scholar
• Peto R, Boreham J, Clark M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years (letter). Lancet 355,1822 (2000)
   Google Scholar
• Howe HL, Wingo PA, Thun MJ et al Annual report to the nation on the status of cancer (1973 —1998), featuring cancers with recent increasing trends. J. Natl Cancer Inst. 93 (11), 824–842 (2001).
   Google Scholar
• Baum M, Saunders C, Meredith S. avast Cancer: a guide for every woman. Oxford University Press (1994).
   Google Scholar
• Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl Cancer Inst. 88(21), 1529–1542 (1996).
   PubMedGoogle Scholar
• Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol 13(2), 513–529 (1995).
   Google Scholar
• Wells SA, Santen RI, Lipton A et al. Medical adrenalectomy with aminoglutethimide clinical studies in postmenopausal patients with metatastic breast carcinoma. Ann. Surg. 187(5), 475–484 (1978).
   PubMedGoogle Scholar
• Goss PE, Powles TJ, Dowsett M et al. Treatment of advanced postmenopausal breast cancer with the aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res. 46,4823–4826 (1986).
   PubMed Web of Science ®Google Scholar
• Atac Trialists' Group. Pharmacokinetics of anastrozole and tamoxifen alone and in combination, during adjuvant endocrine therapy in postmenopausal women: a subprotccol of the Arimidex and Tamoxifen Alone or in Combination (ATAC) trial. Br Cancer85, 317–324 (2001).
   Google Scholar
• Dukes M, Edvards PN, Large M, Smith IK, Boyle T The preclincial pharmacology of Arimidex' (anastrozole, ZD 1033) - a potent, selective aromatase inhibitor. J. Steroid Biochem. Md. Biol. 58,439-445 (1996).
   Google Scholar
• Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth generation aromatase inhibitor. Breast Cancer Res. Treat. 30, 103–111 (1994).
   Google Scholar
• Esparza-Guerra L, Buzdar A. Anastrozole Arimidex does not impair adrenal cortisol or aldosterone synthesis in postmenopausal women with advanced breast cancer. Proc. Ann. Soc. Clin. Oncol 20, (2001) (Abstract 1954).
   Google Scholar
• Muss HB. Endocrine therapy for advanced breast cancer. A review. BE Cancer Res. 7i-eat. 21,15-26 (1992).
   Google Scholar
• Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer. BE J. Cancer 74 (8), 1286–1291 (1996).
   Google Scholar
• Geisler J, Anker G, Dowsett M, Lonning PE. Letrozole suppresses plasma estrogen levels in postmenopausal breast cancer patients more completely than anastrozole. Proc. Ann. Soc. GM. Oncol 19,102a, (2000) (Abstract 394).
   Google Scholar
• Geisler J, Bemsten L, Ottestad B, Lindtjom B, Dowsett M, Lonning PE. Neoadjuvant treatment with anastrozole (Arimidex) causes profound suppression of intra-tumor estrogen levels. Proc. Ann. Soc. GM. Oncol 18,82a, (1999) (Abstract 311).
   Google Scholar
• Cheung KL, Forward DP, Jackson L, Robertson JFR. Combined use of goserelin (Zoladex) and anastrozole (Arimidex) as second-line endocrine therapy in premenopausal women with advanced breast cancer — a study of its clinical and endocrine effects. Eur J. Cancer 37 (Suppl. 5), 8, (2001) (Abstract 0–22).
   Google Scholar
• Yates RA, Dowsett M, Fisher GV et al. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in post-menopausal female volunteers. Br. Cancer 73, 543–548 (1996).
   Google Scholar
• Camp-Sorrell D. Anastrozole: an effective, second-line hormonal treatment for advanced breast cancer. Cancer Bart. 5, 391–393 (1997).
   Google Scholar
• Baldinger SL, Defusco P Focus of anastrozole: an aromatase inhibitor for the treatment of hormonally dependent advanced breast cancer. Formulary31, 363–364 (1996).
   Google Scholar
• Slaughter RI, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. 29,619-624 (1995).
   Google Scholar
• Buzdar AU, Jonat W Howell A et al, for the Arimidex Study Group: anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature Phase III trials. Cancer83, 1142–1152 (1998). Mor comparative study for second-line endocrine therapy.
   Google Scholar
• Nabholtz JM, Buzdar A, Pollak M et al Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women — results of a North American multicenter randomized trial. Oncol 18(22), 3758–3776 (2000).
   Google Scholar
• Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the TARGET (Tamoxifen or Arimidex' Randomized Group Efficacy and Tolerability) Study. J. Clin. aryl 18 (22), 3748–3757 (2000).
   Google Scholar
• Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole (Arimidex') is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast cancer: results of two randomized trials designed for combined analysis. Cancer 92 (9), 2247–2258 (2001). Major comparative study for first-line endocrine therapy.
   Google Scholar
• Dixon JM, Renshaw L, Bellamy C. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Chu Cancer Res. 6, 2229–2235 (2000).
   PubMed Web of Science ®Google Scholar
• Milla-Santos A, Milla I, Palo L, Pulg-Gall M. Anastrozole as neoadjuvant therapy for hormone-dependent locally advanced breast cancer in postmenopausal patients. Proc. ASCO21 (2002) (Abstract 156).
   Google Scholar
• Atac Trialists' Group. Anastrozole alone or in combination with tamoxifen versustamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359,2131-2139 (2002). Mor comparative study for adjuvant endocrine therapy.
   Google Scholar